A high-content imaging assay for the quantification of the Burkholderia pseudomallei induced multinucleated giant cell (MNGC) phenotype in murine macrophages

BMC Microbiology

Rekha G Panchal¹  David DeShazer¹  Sina Bavari¹  Jenifer F Ojeda¹  Douglas J Lane¹  Ricky L Ulrich¹  Brett P Eaton¹  Gianluca Pegoraro² 

[1] Molecular and Translational Sciences Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702-5011, USA;Present Address: Center for Cancer Research, National Cancer Institute/NIH, Bethesda, MD 20892, USA

关键词: Macrophages;    Multinucleated giant cells;    phagocytosis;    High Content imaging;    Burkholderia pseudomallei;   

Others  :  1141350
DOI  :  10.1186/1471-2180-14-98

 received in 2013-12-20, accepted in 2014-04-11,  发布年份 2014

【 摘 要 】

Background

Burkholderia pseudomallei (Bp), a Gram-negative, motile, facultative intracellular bacterium is the causative agent of melioidosis in humans and animals. The Bp genome encodes a repertoire of virulence factors, including the cluster 3 type III secretion system (T3SS-3), the cluster 1 type VI secretion system (T6SS-1), and the intracellular motility protein BimA, that enable the pathogen to invade both phagocytic and non-phagocytic cells. A unique hallmark of Bp infection both in vitro and in vivo is its ability to induce cell-to-cell fusion of macrophages to form multinucleated giant cells (MNGCs), which to date are semi-quantitatively reported following visual inspection.

Results

In this study we report the development of an automated high-content image acquisition and analysis assay to quantitate the Bp induced MNGC phenotype. Validation of the assay was performed using T6SS-1 (∆hcp1) and T3SS-3 (∆bsaZ) mutants of Bp that have been previously reported to exhibit defects in their ability to induce MNGCs. Finally, screening of a focused small molecule library identified several Histone Deacetylase (HDAC) inhibitors that inhibited Bp-induced MNGC formation of macrophages.

Conclusions

We have successfully developed an automated HCI assay to quantitate MNGCs induced by Bp in macrophages. This assay was then used to characterize the phenotype of the Bp mutants for their ability to induce MNGC formation and identify small molecules that interfere with this process. Successful application of chemical genetics and functional reverse genetics siRNA approaches in the MNGC assay will help gain a better understanding of the molecular targets and cellular mechanisms responsible for the MNGC phenotype induced by Bp, by other bacteria such as Mycobacterium tuberculosis, or by exogenously added cytokines.

【 授权许可】

   
2014 Pegoraro et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Galyov EE, Brett PJ, DeShazer D: Molecular insights into Burkholderia pseudomallei and Burkholderia mallei pathogenesis. Annu Rev Microbiol 2010, 64:495-517.
• [2]Sprague LD, Neubauer H: Melioidosis in animals: a review on epizootiology, diagnosis and clinical presentation. J Vet Med B Infect Dis Vet Public Health 2004, 51:305-320.
• [3]Cheng AC, Currie BJ: Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 2005, 18:383-416.
• [4]White NJ: Melioidosis. Lancet 2003, 361:1715-1722.
• [5]Ngauy V, Lemeshev Y, Sadkowski L, Crawford G: Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. J Clin Microbiol 2005, 43:970-972.
• [6]Regulations USCOF: Public Health Security and Bioterrorism Preparedness and Response Act, 107th Congress. In Book Public Health Security and Bioterrorism Preparedness and Response Act, 107th Congress. vol. 42. pp. 107–118. 42nd edition. City: Public Law; 2002:107-118.
• [7]Hoebe K, Janssen E, Beutler B: The interface between innate and adaptive immunity. Nat Immunol 2004, 5:971-974.
• [8]Mackaness GB: The Immunological Basis of Acquired Cellular Resistance. J Exp Med 1964, 120:105-120.
• [9]Chawla A, Nguyen KD, Goh YP: Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol 2011, 11:738-749.
• [10]Ganz T: Iron in innate immunity: starve the invaders. Curr Opin Immunol 2009, 21:63-67.
• [11]Murray PJ, Wynn TA: Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011, 11:723-737.
• [12]Vignery A: Macrophage fusion: the making of osteoclasts and giant cells. J Exp Med 2005, 202:337-340.
• [13]Bouley DM, Ghori N, Mercer KL, Falkow S, Ramakrishnan L: Dynamic nature of host-pathogen interactions in Mycobacterium marinum granulomas. Infect Immun 2001, 69:7820-7831.
• [14]Saunders BM, Frank AA, Orme IM, Cooper AM: CD4 is required for the development of a protective granulomatous response to pulmonary tuberculosis. Cell Immunol 2002, 216:65-72.
• [15]Via LE, Lin PL, Ray SM, Carrillo J, Allen SS, Eum SY, Taylor K, Klein E, Manjunatha U, Gonzales J, Lee EG, Park SK, Raleigh JA, Cho SN, McMurray DN, Flynn JL, Barry CE 3rd: Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun 2008, 76:2333-2340.
• [16]Im JG, Itoh H, Shim YS, Lee JH, Ahn J, Han MC, Noma S: Pulmonary tuberculosis: CT findings–early active disease and sequential change with antituberculous therapy. Radiology 1993, 186:653-660.
• [17]Poey C, Verhaegen F, Giron J, Lavayssiere J, Fajadet P, Duparc B: High resolution chest CT in tuberculosis: evolutive patterns and signs of activity. J Comput Assist Tomogr 1997, 21:601-607.
• [18]Kaplan G, Post FA, Moreira AL, Wainwright H, Kreiswirth BN, Tanverdi M, Mathema B, Ramaswamy SV, Walther G, Steyn LM, Barry CE 3rd, Bekker LG: Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun 2003, 71:7099-7108.
• [19]Ulrichs T, Kosmiadi GA, Trusov V, Jorg S, Pradl L, Titukhina M, Mishenko V, Gushina N, Kaufmann SH: Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J Pathol 2004, 204:217-228.
• [20]Puissegur MP, Botanch C, Duteyrat JL, Delsol G, Caratero C, Altare F: An in vitro dual model of mycobacterial granulomas to investigate the molecular interactions between mycobacteria and human host cells. Cell Microbiol 2004, 6:423-433.
• [21]Chambers TJ: Fusion of hamster macrophages induced by lectins. J Pathol 1977, 123:53-61.
• [22]DeFife KM, Jenney CR, McNally AK, Colton E, Anderson JM: Interleukin-13 induces human monocyte/macrophage fusion and macrophage mannose receptor expression. J Immunol 1997, 158:3385-3390.
• [23]Enelow RI, Sullivan GW, Carper HT, Mandell GL: Induction of multinucleated giant cell formation from in vitro culture of human monocytes with interleukin-3 and interferon-gamma: comparison with other stimulating factors. Am J Respir Cell Mol Biol 1992, 6:57-62.
• [24]Kreipe H, Radzun HJ, Rudolph P, Barth J, Hansmann ML, Heidorn K, Parwaresch MR: Multinucleated giant cells generated in vitro. Terminally differentiated macrophages with down-regulated c-fms expression. Am J Pathol 1988, 130:232-243.
• [25]Lazarus D, Yamin M, McCarthy K, Schneeberger EE, Kradin R: Anti-RMA, a murine monoclonal antibody, activates rat macrophages: II. Induction of DNA synthesis and formation of multinucleated giant cells. Am J Respir Cell Mol Biol 1990, 3:103-111.
• [26]McInnes A, Rennick DM: Interleukin 4 induces cultured monocytes/macrophages to form giant multinucleated cells. J Exp Med 1988, 167:598-611.
• [27]Orentas RJ, Reinlib L, Hildreth JE: Anti-class II MHC antibody induces multinucleated giant cell formation from peripheral blood monocytes. J Leukoc Biol 1992, 51:199-209.
• [28]Postlethwaite AE, Jackson BK, Beachey EH, Kang AH: Formation of multinucleated giant cells from human monocyte precursors. Mediation by a soluble protein from antigen-and mitogen-stimulated lymphocytes. J Exp Med 1982, 155:168-178.
• [29]Sone S, Bucana C, Hoyer LC, Fidler IJ: Kinetics and ultrastructural studies of the induction of rat alveolar macrophage fusion by mediators released from mitogen-stimulated lymphocytes. Am J Pathol 1981, 103:234-246.
• [30]Tabata N, Ito M, Shimokata K, Suga S, Ohgimoto S, Tsurudome M, Kawano M, Matsumura H, Komada H, Nishio M, Ito Y: Expression of fusion regulatory proteins (FRPs) on human peripheral blood monocytes. Induction of homotypic cell aggregation and formation of multinucleated giant cells by anti-FRP-1 monoclonal antibodies. J Immunol 1994, 153:3256-3266.
• [31]Takashima T, Ohnishi K, Tsuyuguchi I, Kishimoto S: Differential regulation of formation of multinucleated giant cells from concanavalin A-stimulated human blood monocytes by IFN-gamma and IL-4. J Immunol 1993, 150:3002-3010.
• [32]Weinberg JB, Hobbs MM, Misukonis MA: Recombinant human gamma-interferon induces human monocyte polykaryon formation. Proc Natl Acad Sci U S A 1984, 81:4554-4557.
• [33]Chambers TJ: Multinucleate giant cells. J Pathol 1978, 126:125-148.
• [34]Most J, Neumayer HP, Dierich MP: Cytokine-induced generation of multinucleated giant cells in vitro requires interferon-gamma and expression of LFA-1. Eur J Immunol 1990, 20:1661-1667.
• [35]Kyriakides TR, Foster MJ, Keeney GE, Tsai A, Giachelli CM, Clark-Lewis I, Rollins BJ, Bornstein P: The CC chemokine ligand, CCL2/MCP1, participates in macrophage fusion and foreign body giant cell formation. Am J Pathol 2004, 165:2157-2166.
• [36]Yagi M, Miyamoto T, Sawatani Y, Iwamoto K, Hosogane N, Fujita N, Morita K, Ninomiya K, Suzuki T, Miyamoto K, Oike Y, Takeya M, Toyama Y, Suda T: DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 2005, 202:345-351.
• [37]Helming L, Gordon S: Molecular mediators of macrophage fusion. Trends Cell Biol 2009, 19:514-522.
• [38]Jay SM, Skokos E, Laiwalla F, Krady MM, Kyriakides TR: Foreign body giant cell formation is preceded by lamellipodia formation and can be attenuated by inhibition of Rac1 activation. Am J Pathol 2007, 171:632-640.
• [39]Helming L, Tomasello E, Kyriakides TR, Martinez FO, Takai T, Gordon S, Vivier E: Essential role of DAP12 signaling in macrophage programming into a fusion-competent state. Sci Signal 2008, 1:ra11.
• [40]Helming L, Winter J, Gordon S: The scavenger receptor CD36 plays a role in cytokine-induced macrophage fusion. J Cell Sci 2009, 122:453-459.
• [41]MacLauchlan S, Skokos EA, Meznarich N, Zhu DH, Raoof S, Shipley JM, Senior RM, Bornstein P, Kyriakides TR: Macrophage fusion, giant cell formation, and the foreign body response require matrix metalloproteinase 9. J Leukoc Biol 2009, 85:617-626.
• [42]Van den Bossche J, Bogaert P, Van Hengel J, Guerin CJ, Berx G, Movahedi K, Van den Bergh R, Pereira-Fernandes A, Geuns JM, Pircher H, Dorny P, Grooten J, De Baetselier P, Van Ginderachter JA: Alternatively activated macrophages engage in homotypic and heterotypic interactions through IL-4 and polyamine-induced E-cadherin/catenin complexes. Blood 2009, 114:4664-4674.
• [43]Yu M, Qi X, Moreno JL, Farber DL, Keegan AD: NF-kappaB signaling participates in both RANKL- and IL-4-induced macrophage fusion: receptor cross-talk leads to alterations in NF-kappaB pathways. J Immunol 2011, 187:1797-1806.
• [44]French CT, Toesca IJ, Wu TH, Teslaa T, Beaty SM, Wong W, Liu M, Schroder I, Chiou PY, Teitell MA, Miller JF: Dissection of the Burkholderia intracellular life cycle using a photothermal nanoblade. Proc Natl Acad Sci U S A 2011, 108:12095-12100.
• [45]Horton RE, Grant GD, Matthews B, Batzloff M, Owen SJ, Kyan S, Flegg CP, Clark AM, Ulett GC, Morrison N, Peak IR, Beacham IR: Quorum sensing negatively regulates multinucleate cell formation during intracellular growth of Burkholderia pseudomallei in macrophage-like cells. PLoS One 2013, 8:e63394.
• [46]Kespichayawattana W, Rattanachetkul S, Wanun T, Utaisincharoen P, Sirisinha S: Burkholderia pseudomallei induces cell fusion and actin-associated membrane protrusion: a possible mechanism for cell-to-cell spreading. Infect Immun 2000, 68:5377-5384.
• [47]Wong KT, Puthucheary SD, Vadivelu J: The histopathology of human melioidosis. Histopathology 1995, 26:51-55.
• [48]Boddey JA, Day CJ, Flegg CP, Ulrich RL, Stephens SR, Beacham IR, Morrison NA, Peak IR: The bacterial gene lfpA influences the potent induction of calcitonin receptor and osteoclast-related genes in Burkholderia pseudomallei-induced TRAP-positive multinucleated giant cells. Cell Microbiol 2007, 9:514-531.
• [49]Brett PJ, Burtnick MN, Su H, Nair V, Gherardini FC: iNOS activity is critical for the clearance of Burkholderia mallei from infected RAW 264.7 murine macrophages. Cell Microbiol 2008, 10:487-498.
• [50]Burtnick MN, Brett PJ, Nair V, Warawa JM, Woods DE, Gherardini FC: Burkholderia pseudomallei type III secretion system mutants exhibit delayed vacuolar escape phenotypes in RAW 264.7 murine macrophages. Infect Immun 2008, 76:2991-3000.
• [51]Harley VS, Dance DA, Drasar BS, Tovey G: Effects of Burkholderia pseudomallei and other Burkholderia species on eukaryotic cells in tissue culture. Microbios 1998, 96:71-93.
• [52]Pilatz S, Breitbach K, Hein N, Fehlhaber B, Schulze J, Brenneke B, Eberl L, Steinmetz I: Identification of Burkholderia pseudomallei genes required for the intracellular life cycle and in vivo virulence. Infect Immun 2006, 74:3576-3586.
• [53]Suparak S, Kespichayawattana W, Haque A, Easton A, Damnin S, Lertmemongkolchai G, Bancroft GJ, Korbsrisate S: Multinucleated giant cell formation and apoptosis in infected host cells is mediated by Burkholderia pseudomallei type III secretion protein BipB. J Bacteriol 2005, 187:6556-6560.
• [54]Whitmore A: An Account of a Glanders-like Disease occurring in Rangoon. J Hyg 1913, 13:1-34 31.
• [55]Schell MA, Ulrich RL, Ribot WJ, Brueggemann EE, Hines HB, Chen D, Lipscomb L, Kim HS, Mrazek J, Nierman WC, Deshazer D: Type VI secretion is a major virulence determinant in Burkholderia mallei. Mol Microbiol 2007, 64:1466-1485.
• [56]Shalom G, Shaw JG, Thomas MS: In vivo expression technology identifies a type VI secretion system locus in Burkholderia pseudomallei that is induced upon invasion of macrophages. Microbiology 2007, 153:2689-2699.
• [57]Muangsombut V, Suparak S, Pumirat P, Damnin S, Vattanaviboon P, Thongboonkerd V, Korbsrisate S: Inactivation of Burkholderia pseudomallei bsaQ results in decreased invasion efficiency and delayed escape of bacteria from endocytic vesicles. Arch Microbiol 2008, 190:623-631.
• [58]Burtnick MN, Brett PJ, Harding SV, Ngugi SA, Ribot WJ, Chantratita N, Scorpio A, Milne TS, Dean RE, Fritz DL, Peacock SJ, Prior JL, Atkins TP, Deshazer D: The cluster 1 type VI secretion system is a major virulence determinant in Burkholderia pseudomallei. Infect Immun 2011, 79:1512-1525.
• [59]Utaisincharoen P, Arjcharoen S, Limposuwan K, Tungpradabkul S, Sirisinha S: Burkholderia pseudomallei RpoS regulates multinucleated giant cell formation and inducible nitric oxide synthase expression in mouse macrophage cell line (RAW 264.7). Microb Pathog 2006, 40:184-189.
• [60]Toesca IJ, French CT, Miller JF: The T6SS-5 VgrG spike protein mediates membrane fusion during intercellular spread by pseudomallei-group Burkholderia species. Infect Immun 2014, 82:1436-1444.
• [61]Bullen A: Microscopic imaging techniques for drug discovery. Nat Rev Drug Discov 2008, 7:54-67.
• [62]Christophe T, Jackson M, Jeon HK, Fenistein D, Contreras-Dominguez M, Kim J, Genovesio A, Carralot JP, Ewann F, Kim EH, Lee SY, Kang S, Seo MJ, Park EJ, Skovierova H, Pham H, Riccardi G, Nam JY, Marsollier L, Kempf M, Joly-Guillou ML, Oh T, Shin WK, No Z, Nehrbass U, Brosch R, Cole ST, Brodin P: High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog 2009, 5:e1000645.
• [63]Gurumurthy RK, Maurer AP, Machuy N, Hess S, Pleissner KP, Schuchhardt J, Rudel T, Meyer TF: A loss-of-function screen reveals Ras- and Raf-independent MEK-ERK signaling during Chlamydia trachomatis infection. Sci Signal 2010, 3:ra21.
• [64]Lang P, Yeow K, Nichols A, Scheer A: Cellular imaging in drug discovery. Nat Rev Drug Discov 2006, 5:343-356.
• [65]Low J, Stancato L, Lee J, Sutherland JJ: Prioritizing hits from phenotypic high-content screens. Curr Opin Drug Discov Devel 2008, 11:338-345.
• [66]Misselwitz B, Dilling S, Vonaesch P, Sacher R, Snijder B, Schlumberger M, Rout S, Stark M, Von Mering C, Pelkmans L, Hardt WD: RNAi screen of Salmonella invasion shows role of COPI in membrane targeting of cholesterol and Cdc42. Mol Syst Biol 2011, 7:474.
• [67]Perlman ZE, Slack MD, Feng Y, Mitchison TJ, Wu LF, Altschuler SJ: Multidimensional drug profiling by automated microscopy. Science 2004, 306:1194-1198.
• [68]Tanaka M, Bateman R, Rauh D, Vaisberg E, Ramachandani S, Zhang C, Hansen KC, Burlingame AL, Trautman JK, Shokat KM, Adams CL: An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol 2005, 3:e128.
• [69]Young DW, Bender A, Hoyt J, McWhinnie E, Chirn GW, Tao CY, Tallarico JA, Labow M, Jenkins JL, Mitchison TJ, Feng Y: Integrating high-content screening and ligand-target prediction to identify mechanism of action. Nat Chem Biol 2008, 4:59-68.
• [70]Warawa J, Woods DE: Type III secretion system cluster 3 is required for maximal virulence of Burkholderia pseudomallei in a hamster infection model. FEMS Microbiol Lett 2005, 242:101-108.
• [71]Bierne H, Hamon M, Cossart P: Epigenetics and bacterial infections. Cold Spring Harbor Perspectives in Medicine 2012, 2:a010272.
• [72]Heine HS, England MJ, Waag DM, Byrne WR: In vitro antibiotic susceptibilities of Burkholderia mallei (causative agent of glanders) determined by broth microdilution and E-test. Antimicrob Agents Chemother 2001, 45:2119-2121.
• [73]Wilson K: Preparation of genomic DNA from bacteria. Curr Protoc Mol Biol 2001, 00:2.4.1-2.4.5.
• [74]Hamad MA, Zajdowicz SL, Holmes RK, Voskuil MI: An allelic exchange system for compliant genetic manipulation of the select agents Burkholderia pseudomallei and Burkholderia mallei. Gene 2009, 430:123-131.
• [75]DeShazer D, Brett PJ, Carlyon R, Woods DE: Mutagenesis of Burkholderia pseudomallei with Tn5-OT182: isolation of motility mutants and molecular characterization of the flagellin structural gene. J Bacteriol 1997, 179:2116-2125.
• [76]Ulrich RL, Amemiya K, Waag DM, Roy CJ, DeShazer D: Aerogenic vaccination with a Burkholderia mallei auxotroph protects against aerosol-initiated glanders in mice. Vaccine 2005, 23:1986-1992.